Sex-Specific Contribution of Cardiometabolic Index in Predicting Metabolic Dysfunction-Associated Fatty Liver Disease: Insights from a General Population

被引:5
|
作者
Gu, Dongxing [1 ]
Lu, Yayun [1 ]
Xu, Baiqing [1 ,3 ]
Tang, Xuefeng [2 ,3 ]
机构
[1] Huadong Sanat, Hlth Examinat Ctr, Wuxi, Peoples R China
[2] Huadong Sanat, Dept Hlth Nursing, Wuxi, Peoples R China
[3] Huadong Sanat, 67 Jinyuan Rd, Wuxi 214065, Peoples R China
关键词
metabolic dysfunction-associated fatty liver disease; cardiometabolic index; sex; general population; predicting value; LIPOPROTEIN-CHOLESTEROL RATIO; TO-HEIGHT RATIO; HEPATIC STEATOSIS; RISK; OBESITY; TRIGLYCERIDES; ADIPOSITY; LIPIDS; MAFLD;
D O I
10.2147/DMSO.S437413
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objective: Evidence suggests that cardiometabolic index (CMI) has been identified as a novel obesity-related index associated with diabetes, hypertension, and cardiovascular disease. Current evidence suggests that the differences in sex hormones and regional fat distribution in both sexes are directly correlated with metabolic dysfunction-associated fatty liver disease (MAFLD) risk. This study aimed to investigate the diagnostic value of CMI in MAFLD in both sexes.Methods: This retrospective study included 6107 subjects who underwent annual health check-ups from March 2021 to January 2022. CMI was calculated by multiplying the ratio of triglycerides and high-density lipoprotein cholesterol (TG/HDL-C) by waist-to-height ratio (WHtR). Multivariable logistic regression analysis and restricted cubic spline were used to investigate the association of CMI and MAFLD risk. Receiver operating characteristic curve analysis was conducted for the exploration of the diagnostic accuracies of obesity-related indicators. Areas under the curves (AUCs) with 95% CIs were calculated.Results: Prevalence of MAFLD increased with elevated quartiles of CMI in both sexes. The median (IQR) age was 46.00 (18.00) years. Multivariate logistic regression analyses showed that higher CMI was independently associated with MAFLD, in which every additional standard deviation (SD) of CMI increased the risk of MAFLD (OR=2.72, 95% CI:2.35-3.15 for males; OR=3.26, 95% CI:2.36-4.51 for females). Subjects in the fourth quartile of CMI had the highest odds of MAFLD for males (OR=15.82, 95% CI:11.84-21.14) and females (OR=22.60, 95% CI:9.52-53.65)(all P for trend<0.001). Besides, CMI had a non-linearity association with MAFLD (all P for non-linearity<0.001). Furthermore, CMI exhibited the largest AUC compared to other obesity-related indexes in terms of discriminating MAFLD in males (AUC=0.796, 95% CI:0.782-0.810) and females (AUC=0.853, 95% CI:0.834-0.872).Conclusion: CMI was a convenient indicator for the screening of MAFLD among Chinese adults. Females with high CMI had a better diagnostic value for MAFLD than males.
引用
收藏
页码:3871 / 3883
页数:13
相关论文
共 50 条
  • [41] Updates in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Children
    Rupasinghe, Kushila
    Hind, Jonathan
    Hegarty, Robert
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2023, 77 (05): : 583 - 591
  • [42] Are dairy products the answer to metabolic dysfunction-associated fatty liver disease?
    Lau, Kristopher Cho-Hei
    Wong, Vincent Wai-Sun
    HEPATOLOGY INTERNATIONAL, 2024, 18 (03) : 870 - 872
  • [43] The Relationship Between Ferroptosis and Metabolic Dysfunction-Associated Fatty Liver Disease
    Chen, Ke-qian
    Wang, Shu-zhi
    Lei, Hai-bo
    Liu, Xiang
    LIVER INTERNATIONAL, 2025, 45 (04)
  • [44] Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B
    Huang, Shang -Chin
    Kao, Jia-Horng
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2022, 121 (11) : 2148 - 2151
  • [45] Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
    Song, Byeong Geun
    Choi, Sung Chul
    Goh, Myung Ji
    Kang, Wonseok
    Sinn, Dong Hyun
    Gwak, Geum-Youn
    Paik, Yong-Han
    Choi, Moon Seok
    Lee, Joon Hyeok
    Paik, Seung Woon
    JHEP REPORTS, 2023, 5 (09)
  • [46] Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies
    Al Hashmi, Khamis
    Giglio, Rosaria Vincenza
    Stoian, Anca Pantea
    Patti, Angelo Maria
    Al Waili, Khalid
    Al Rasadi, Khalid
    Ciaccio, Marcello
    Rizzo, Manfredi
    FRONTIERS IN NUTRITION, 2024, 11
  • [47] Association between the Fatty Liver Index, Metabolic Dysfunction-Associated Steatotic Liver Disease, and the Risk of Kidney Stones
    Zhang, Fan
    Li, Wenjian
    KIDNEY & BLOOD PRESSURE RESEARCH, 2025, 50 (01): : 115 - 130
  • [48] Metabolic dysfunction-associated fatty liver disease in people living with HIV
    Michel, Maurice
    Labenz, Christian
    Armandi, Angelo
    Kaps, Leonard
    Kremer, Wolfgang Maximilian
    Galle, Peter R.
    Grimm, Daniel
    Sprinzl, Martin
    Schattenberg, Joern M.
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [49] Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis
    Wang, Xiaolin
    Xie, Qing
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2022, 10 (01) : 128 - 133
  • [50] Metabolic Dysfunction-Associated Fatty Liver Disease, Statins, and Atherosclerotic Cardiovascular Disease
    Chang, Hui-Chin
    Gau, Shuo-Yan
    AMERICAN JOURNAL OF MEDICINE, 2024, 137 (01): : E14 - E14